1-(2-氟吡啶-4-基)乙酮 | 111887-72-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2-氟吡啶-4-基)乙酮
• 中文别名: 2-氟-4-乙酰吡啶
• 英文名称: 2-fluoro-4-acetylpyridine
• 英文别名: 1-(2-fluoropyridin-4-yl)ethan-1-one；1-(2-Fluoropyridin-4-YL)ethanone
• CAS: 111887-72-0
• 化学式: C₇H₆FNO
• mdl: MFCD09263924
• 分子量: 139.129
• InChiKey: OJYXKBMRTTZINQ-UHFFFAOYSA-N

物化性质

• 熔点：
  37.5-39.0 °C
• 沸点：
  231.6±20.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  1-(2-氟吡啶-4-基)乙酮 在 溴 作用下， 生成 2-bromo-1-(2-fluoropyridin-4-yl)ethanone
  参考文献：
  名称：

  NOVEL GPR119 AGONIST COMPOUNDS

  摘要：

  本发明涉及公式（I）的新化合物，其制备方法以及包含这些化合物的组合物。

  公开号：

  US20170291894A1
• 作为产物：
  描述：

  2-氟吡啶 在 manganese(IV) oxide 、 正丁基锂 、 四甲基乙二胺 作用下， 以 甲苯 为溶剂， 反应 14.5h， 生成 1-(2-氟吡啶-4-基)乙酮
  参考文献：
  名称：

  A new convergent route to 1-substituted ellipticines

  摘要：

  1-(2-Fluoro-4-pyridyl)ethanone was synthesized from 2-fluoropyridine and was ortho-lithiated after activation as the propylene glycol ketal. The resulting 3-lithio derivative was trapped by various electrophiles but reacted in low yield with N-protected 3-indolecarbaldehyde. Model compounds 1-[[[2-(diethylamino)ethyl]amino]-3-pyridyl]ethanol and -ethanone were prepared and selectively condensed with indole. 1-[[[2-(Diethylamino)-ethyl]amino]-3-pyridyl]ethanol and -ethanone bearing a ketal-protected acetyl moiety at the C-4 position have been obtained in high yields starting from the propylene glycol ketal of 1-(2-fluoro-4-pyridyl)ethanone. These reagents could not be condensed with indole either due to side reactions between the C-3 and C-4 functions or to steric hindrance. 1-(2-Substituted-4-bromo-3-pyridyl)ethanols were synthesized via a metalation/halogen-dance strategy starting from 2-fluoropyridine. 1-(2,4-Dihalo-3-pyridyl)-1-chloroethane could be prepared and condensed with 1-indolylmagnesium iodide, which allowed the construction of the expected 3-[1-(3-pyridyl)ethyl]indole skeleton. Functionalization of the pyridine C-4 bromo position was achieved by a vinylstannane cross-coupling reaction using a palladium(0) catalyst. Acidic treatment of the resulting 4-(1-ethoxyethenyl)pyridine led to 1-fluoroellipticine. The whole sequence requires six steps from indole and 2-fluoropyridine and allows an attractive overall yield.

  DOI：

  10.1021/jo00028a032

文献信息

• [EN] 2-PYRIDINYL[7-(SUBSTITUTED-PYRIDIN-4-YL) PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]METHANONES<br/>[FR] 2-PYRIDINYL[7-(PYRIDIN-4-YLE SUBSTITUE)PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]METHANONES
  申请人：DOV PHARMACEUTICAL INC

  公开号：WO2005084439A1

  公开（公告）日：2005-09-15

  The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5­-a]pyrimidin-3-yl]methanones with at least one substituent on the 4-pyridinyl ring having the chemical structure of formula (I): The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula: (I) in to modulate GABA and GABA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and/or GABA receptors.

  本发明提供了具有化学结构式(I)的新型2-吡啶基[7-(吡啶-4-基)吡唑并[1,5-a]嘧啶-3-基]甲酮，其中4-吡啶基环上至少有一个取代基。该发明还提供了应用化学式(I)的新型2-吡啶基[7-(吡啶-4-基)吡唑并[1,5-a]嘧啶-3-基]甲酮的组合物和方法，用于调节GABA和GABA受体生理，以引发哺乳动物主体中的治疗反应，以缓解神经系统或精神障碍，包括中风、头部创伤、癫痫、疼痛、偏头痛、情绪障碍、焦虑、创伤后应激障碍、强迫性障碍、躁狂、双相障碍、精神分裂症、癫痫发作、抽搐、耳鸣、包括阿尔茨海默病、肌萎缩侧索硬化和帕金森病在内的神经退行性疾病、亨廷顿舞蹈症、抑郁症、双相障碍、躁狂、三叉神经痛和其他神经痛、神经痛、高血压、脑缺血、心律失常、肌张力过高、物质滥用、肌阵挛、本体震颤、运动障碍和其他由GABA和/或GABA受体介导的新生儿脑出血、痉挛性瘫痪以及痉挛性瘫痪，以及其他精神和神经障碍的方法。
• [EN] ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS
  申请人：DISCUVA LTD

  公开号：WO2019086890A1

  公开（公告）日：2019-05-09

  The present invention relates to compounds of general formula (II),to compositions comprising these compounds and to methods of treating Enterobacteriaceae bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Enterobacteriaceae.

  本发明涉及一般式（II）的化合物，包括这些化合物的组合物，以及使用这些化合物治疗肠杆菌科细菌疾病和感染的方法。这些化合物在治疗肠杆菌科感染和疾病方面具有应用。
• 4-Pyridylanilinothiazoles That Selectively Target von Hippel−Lindau Deficient Renal Cell Carcinoma Cells by Inducing Autophagic Cell Death
  作者：Michael P. Hay、Sandra Turcotte、Jack U. Flanagan、Muriel Bonnet、Denise A. Chan、Patrick D. Sutphin、Phuong Nguyen、Amato J. Giaccia、William A. Denny

  DOI：10.1021/jm901457w

  日期：2010.1.28

  recently identified a 4-pyridyl-2-anilinothiazole (PAT) with selective cytotoxicity against VHL-deficient renal cells mediated by induction of autophagy and increased acidification of autolysosomes. We report exploration of structure−activity relationships (SAR) around this PAT lead. Analogues with substituents on each of the three rings, and various linkers between rings, were synthesized and tested in

  肾细胞癌 (RCC) 对预后不良的晚期 RCC 的标准治疗无效；因此，晚期 RCC 的治疗代表了未满足的临床需求。von Hippel-Lindau (VHL) 肿瘤抑制基因在大多数 RCC 中发生突变或失活。我们最近发现了一种 4-pyridyl-2-anilinothiazole (PAT)，它对 VHL 缺陷的肾细胞具有选择性的细胞毒性，这种毒性是通过诱导自噬和增加自溶酶体的酸化来介导的。我们报告了围绕此 PAT 导联的构效关系 (SAR) 的探索。使用成对的 RCC4 细胞系合成并在体外测试三个环中每个环上具有取代基的类似物以及环之间的各种接头。描述不同化学特征对效力的相对空间贡献的等高线图说明了一个区域，与吡啶环相邻，具有进一步发展的潜力。探索这个域的例子验证了这种方法，并可能为开发这种新的化学型作为 RCC 治疗的靶向方法提供机会。
• [EN] 18F LABELLED THIAZOLYLHYDRAZONE DERIVATIVES<br/>[FR] DÉRIVÉS DE THIAZOLYLHYDRAZONE MARQUÉS AU 18F
  申请人：GE HEALTHCARE LTD

  公开号：WO2016097351A1

  公开（公告）日：2016-06-23

  The present invention relates to compounds of Formula (I) wherein R1 and R2 are independently selected from 19F and 18F having selective binding for MAO-B as compared with MAO-A. The invention also provides radioactive versions of these compounds, and precursor compounds for the synthesis of these radioactive compounds. The radioactive compounds of the invention can find use for in vivo imaging applications.

  本发明涉及式（I）化合物，其中R1和R2分别选自19F和18F，与MAO-A相比具有对MAO-B的选择性结合。该发明还提供这些化合物的放射性版本，以及用于合成这些放射性化合物的前体化合物。本发明的放射性化合物可用于体内成像应用。
• [EN] HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT<br/>[FR] COMPOSÉS HÉTÉROARYLE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2009114552A1

  公开（公告）日：2009-09-17

  Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing diseases such as cancer, and in particular cancers resulting from von Hippel-Lindau disease. The compounds of the invention may be administered in combination with another therapeutic agent.

  本文提供了新颖的杂环芳基化合物，包含这些化合物的组合物，以及包括给予这些化合物的治疗或预防方法。这些化合物在靶向冯·希普尔-林道（von Hippel-Lindau）基因缺陷细胞和诱导自噬性细胞死亡方面具有有效性。这些方法旨在治疗或预防癌症等疾病，特别是由冯·希普尔-林道疾病引起的癌症。本发明的化合物可以与另一种治疗剂联合给药。